0GQU.LSE Active Biotech AB
- Market cap
- SEK 8.09M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2021.
Is 0GQU.LSE undervalued?
Graham numberThe Graham number of Active Biotech AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Active Biotech AB fundamental analysis
No fundamental analysis for Active Biotech AB yet.
Active Biotech AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a …
Full company profileActive Biotech AB financial statements
2021 annualized: Fiscal year 2021 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2021, the balance sheet is the latest quarter. Figures change when the annual report is published.
Active Biotech AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 Anlz |
|---|---|---|---|---|---|
| Cash Flow | |||||
| Operating Cash Flow | -46.4M | -40.6M | -35.8M | -32.2M | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | - |
What these items mean
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
Active Biotech AB dividends
Active Biotech AB has not paid dividends in the last 8 fiscal years.
Last stock split: 0.01:1 on Jun 3, 2026.
Who owns Active Biotech AB
- Insiders 16.99%
- Institutions 6.23%
- Public & others 76.79%
- Shares outstanding 145M
- Free float 22.7M
Active Biotech AB company profile
- Company name
- Active Biotech AB
- Ticker
- 0GQU.LSE
- ISIN
- SE0001137985
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 5
- Fiscal year end
- December
- Address
- Scheelevägen 22, Lund, Sweden, 223 63
- Phone
- 46 46 19 20 00
- Website
- activebiotech.com
About Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company has collaboration with Abramson Cancer Center, University of Pennsylvania, MD Anderson Cancer Center, Texas and Stictching-Haemato-Oncologie Volwassenen Netherlands, as well as Stanford Medicine and the Global Ophthalmic Research Center. The company was incorporated in 1983 and is headquartered in Lund, Sweden.
Active Biotech AB management
3- Ms. Helen Tuvesson Ph.D.President & CEO · born 1962
- Mr. Hans KolamChief Financial Officer · born 1951
- Dr. Erik Vahtola M.D., Ph.D.Chief Medical Officer · born 1976